|
English
|
正體中文
|
简体中文
|
Total items :2875232
|
|
Visitors :
54178088
Online Users :
853
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
|
|
|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"xu j"
Showing items 31-40 of 231 (24 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 國立成功大學 |
2022 |
Thermally Stable D2h Symmetric Donor-π-Donor Porphyrins as Hole-Transporting Materials for Perovskite Solar Cells
|
Mai, C.-L.;Xiong, Q.;Li, X.;Chen, J.-Y.;Chen, J.-Y.;Chen, Chen C.-C.;Xu, J.;Liu, C.;Yeh, C.-Y.;Gao, P. |
| 臺大學術典藏 |
2021-10-28T07:11:17Z |
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
|
Choon S.E.; Lebwohl M.G.; Marrakchi S.; Burden A.D.; TSEN-FANG TSAI; Morita A.; Navarini A.A.; Zheng M.; Xu J.; Turki H.; Rajeswari S.; Deng H.; Tetzlaff K.; Thoma C.; Bachelez H. |
| 臺大學術典藏 |
2021-10-15T08:26:43Z |
Prostate sphere-forming stem cells are derived from the P63-expressing basal compartment
|
Huang Y.; Hamana T.; Liu J.; Wang C.; An L.; You P.; JULIA YU-FONG CHANG; Xu J.; McKeehan W.L.; Wang F. |
| 臺大學術典藏 |
2021-10-15T08:26:43Z |
Type 2 fibroblast growth factor receptor signaling preserves stemness and prevents differentiation of prostate stem cells from the basal compartment
|
Huang Y.; Hamana T.; Liu J.; Wang C.; An L.; You P.; JULIA YU-FONG CHANG; Xu J.; Jin C.; Zhang Z.; McKeehan W.L.; Wang F. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
|
ANN-LII CHENG; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. |
| 臺大學術典藏 |
2021-09-01T01:53:59Z |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
|
ANN-LII CHENG; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
| 臺大學術典藏 |
2021-08-05T02:42:20Z |
An Injectable, Electroconductive Hydrogel/Scaffold for Neural Repair and Motion Sensing
|
Xu J;Wong C.-W;Hsu S.-H.; Xu J; Wong C.-W; Hsu S.-H.; SHAN-HUI HSU |
Showing items 31-40 of 231 (24 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
